Updates - Temple Therapeutics

Diagnostic and prognostic biomarkers associated with histotype in advanced epithelial ovarian cancer

Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma

Publication: Global recommendations on adhesion prophylaxis in gynaecological laparoscopic surgery

Temple Therapeutics spins out Temple Orthobiologics

Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer

Publication: Specific biomarker for early-stage ovarian cancer

Groundbreaking Human Trial for Patients Suffering with Post-surgical Adhesion Related Complications

Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023

A randomized double-blind controlled proof-of-concept study of alanyl-glutamine for reduction of post-myomectomy adhesions